Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial
G-D Batty, Q Li, R Huxley, S Zoungas, B-A Taylor, B Neal, B de Galan, M Woodward, S-B Harrap, S Colagiuri, A Patel, J Chalmers
European Psychiatry | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | Published : 2013
Awarded by Medical Research Council
As a principal investigator for ADVANCE, John Chalmers holds research grants from Servier, which are administered through the University of Sydney. John Chalmers, Bruce Neal, Anushka Patel, Sophia Zoungas, and Mark Woodward have all received lecturing fees from Servier.The ADVANCE trial was funded by grants from Servier and the National Health and Medical Research Council of Australia. These sponsors had no role in the design of the study, data collection, data analysis, data interpretation, and the writing of the manuscript. Study data were not made available to the sponsors. The Management Committee, whose membership did not include any sponsor representatives, had final responsibility for the decision to submit this manuscript for publication. The authors had full access to the study data and take responsibility for the accuracy of the analysis. David Batty is a welcome trust career development fellow. The Medical Research Council (MRC) Social and Public Health Sciences Unit receives funding from the UK MRC and the Chief Scientist Office at the Scottish Government Health Directorates. The Centre for Cognitive Ageing and Cognitive Epidemiology is supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Medical Research Council, and the University of Edinburgh as part of the cross-council lifelong health and well-being initiative.